U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.

Name: U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
Author: Dottino, Joseph A

U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis. — المؤلف: Dottino, Joseph A — Obstetrics and gynecology 20200122

المؤلف: Dottino, Joseph A
النشر: Obstetrics and gynecology 20200122
الوصف: 795-802 p.
الموضوعات: Aged؛ Antineoplastic Agents؛ Carcinoma, Ovarian Epithelial؛ Cost-Benefit Analysis؛ Decision Support Techniques؛ Disease-Free Survival؛ Drug Approval؛ Female